Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampicin on Selumetinib PK
NCT02046850Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selumetinib in solid tumor, sponsored by AstraZeneca. Primary endpoint: Area Under the Curve (AUC) from time zero to infinity. Started Feb 2014; status: completed.
02
Drugs
selumetinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02046850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02046850.